The DoD’s Chemical and Biological Defense Program Awards Extend Biosciences a Phase 1 SBIR

Posted on February 21, 2020

A Phase 1 SBIR was awarded to advance the development of a long duration, novel opioid medical countermeasure for use by Department of Defense Service Members in far-forward deployed settings.